Nom du produit:Methyl 6-cyano-1H-indole-3-carboxylate
IUPAC Name:methyl 6-cyano-1H-indole-3-carboxylate
- CAS：1357147-38-6
- Formule moléculaire：C11H8N2O2
- Pureté：95%
- Numéro de catalogue：CM241331
- Poids moléculaire：200.2
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1357147-38-6
- Formule moléculaire:C11H8N2O2
- Point de fusion:-
- Code SMILES:O=C(C1=CNC2=C1C=CC(C#N)=C2)OC
- Densité:
- Numéro de catalogue:CM241331
- Poids moléculaire:200.2
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Indoles
- Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.
- indole company
- As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.
Column Infos
- Alectinib
- Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
